CN117843804A

CN117843804A - Single-domain antibody tandem molecule and sequence, product, preparation and application thereof

Info

Publication number: CN117843804A
Application number: CN202311864475.0A
Authority: CN
Inventors: 刘拥军; 刘广洋; 张晨亮; 徐晓丹; 周敬文; 崔嫄汭
Original assignee: Beijing Beilai Pharmaceutical Co ltd
Current assignee: Beijing Beilai Pharmaceutical Co ltd
Priority date: 2023-12-29
Filing date: 2023-12-29
Publication date: 2024-04-09

Abstract

The invention belongs to the technical field of cell immunology, and particularly relates to a single-domain antibody tandem molecule and a sequence, a product, preparation and application thereof. The invention provides an antibody comprising: (1) The amino acid sequence of the first single domain antibody comprises HCDR1 shown as SEQ ID NO. 1, HCDR2 shown as SEQ ID NO. 2 and HCDR3 shown as SEQ ID NO. 3; (2) The amino acid sequence of the second single domain antibody comprises HCDR4 shown as SEQ ID NO. 4, HCDR5 shown as SEQ ID NO. 5 and HCDR6 shown as SEQ ID NO. 6. The antibody of the invention has strong binding capacity, strong blocking capacity and strong stability.

Description

Single-domain antibody tandem molecule and sequence, product, preparation and application thereof

Technical Field

The invention belongs to the technical field of cell immunology, and particularly relates to a single-domain antibody tandem molecule and a sequence, a product, preparation and application thereof.

Background

There are six members of the IL-17 family, including IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F, where IL-17A is the fundamental member of the family and these cytokines are dimer molecules of 23-36kD consisting of 163-202 amino acids. NK cells, CD8+ cells, macrophages, dendritic cells, and the like can produce IL-17A, but the major source of IL-17A is the novel subtype of CD4 helper T cells-Th 17 cells. Functionally, IL-17A is a pro-inflammatory cytokine, an early initiating factor in T lymphocyte-mediated inflammatory responses, with powerful pro-inflammatory and neutrophil activation effects. IL-17A acts on a variety of cells such as T lymphocytes, bone marrow mononuclear cells, bone marrow stromal cells, epithelial cells, endothelial cells, fibroblasts, etc. by binding to its receptor, inducing the production of a number of pro-inflammatory factors (TNF- α, IL-1β, G-CSF, IL-8, etc.) or pro-fibrotic factors IL-6 by the corresponding cells to participate in the disease process. IL-17A, once bound to the receptor, activates the linker molecule TRAF6, which serves its biological function by activating NF-kappa B and MAP kinase families (including ERK1, ERK2, SAPK/JNK, P38, etc. signaling molecules).

Monoclonal antibodies (mAbs) refer to antibodies produced by single B cell cloning that are directed against only one specific epitope, and are produced primarily by hybridoma antibody technology. Monoclonal antibodies have become a new pharmaceutical form due to their high specificity and high targeting selectivity, and they can block soluble mediators of diseases, such as cytokines and receptors. The monoclonal antibody is applied to the treatment of diseases, and has the advantages of immunosuppressive and anti-inflammatory drugs for treating autoimmune diseases.

Chinese patent CN110585430a discloses a pharmaceutical composition of humanized anti-human IL-17A monoclonal antibody, which comprises anti-human IL-17A monoclonal antibody and a pharmaceutically acceptable carrier, which comprises buffer, stabilizer and surfactant. The pharmaceutical composition can effectively improve the stability of the anti-human IL-17A monoclonal antibody under the conditions of pressurization (high temperature, freeze thawing, vibration and the like), acceleration and long-term refrigeration, and can improve the safety of clinical use. However, monoclonal antibodies are used for preparing pharmaceutical compositions for treating diseases, which can generate drug resistance and have certain side effects, and the preparation process is complex and the cost is high.

Unlike conventional monoclonal antibodies, single domain antibodies lack a light chain, and there is no CH1 region between the variable region and the hinge region of the heavy chain, only the variable region of the heavy chain (VHH) and two conventional CH2 and CH3 regions. The molecular mass of single domain antibodies is only one tenth that of traditional antibodies, being the smallest functional antigen binding fragment, due to its small molecular size, is capable of penetrating into the cell gap and tissues, and is capable of crossing the blood brain barrier and functioning in the central nervous system. The single domain antibody has stable structure, low immunogenicity and easy humanized reconstruction. The CDR3 of the single domain antibody is longer, and the binding mode with the antigen is more flexible.

Monoclonal antibody treatment has certain defects, and the research on IL-17A single-domain antibodies in the prior art is less, so that the development of a single-domain antibody drug with high stability, strong affinity and low production cost is a technical problem to be solved at present.

The present inventors have focused on the development of anti-IL-17A antibodies, further technical development based on the screened 9 single domain antibodies (filed in another application), resulting in 12 single domain antibody combinations with relatively improved affinity, blocking effect and stability, and separately claimed 12 different single domain antibody combinations based on the relevant regulations of patent law singleness.

The present invention is a patent application directed to one of the above 12 single domain antibody combination antibodies.

Based on the above, the inventors have developed a genetically modified stem cell technology and subsequent application technology, and based on the relevant regulations of the patent law singleness, the protection is respectively requested for 3 different genetically modified stem cells and 3 different applications.

For the convenience of understanding the technical solution of the present invention, reference is optionally made to other patent application documents of this project.

Disclosure of Invention

Terminology and statement of the invention:

1. as used herein, the term "amino acid": comprising natural amino acids, synthetic amino acids, amino acid analogs and amino acid mimics that function in a manner similar to natural amino acids. Natural amino acids are amino acids encoded by the genetic code. Amino acid analogs refer to those compounds that have the same basic chemical structure as a naturally occurring amino acid. Amino acids may be referred to herein by their commonly known three-letter symbols or by the one-letter symbols recommended by the IUPAC-IUB biochemical nomenclature committee (Biochemical Nomenclature Commission).

2. As used herein, the term "antibody": refers to a polypeptide or fragment thereof that specifically binds to and recognizes an antigen, including the framework regions of immunoglobulin genes. The use of the term antibody is meant to include whole antibodies and antigen-binding fragments thereof. The term antibody encompasses monospecific antibodies, bispecific antibodies, and multispecific antibodies so long as they exhibit the desired biological activity or function.

3. As used herein, the terms "single domain antibody (VHH)", "single domain antibody" (singledomain antibody, sdAb, or nanobody) have the same meaning, referring to the variable region of a cloned antibody heavy chain, a single domain antibody consisting of only one heavy chain variable region is constructed, which is the smallest antigen-binding fragment with complete function. Typically, after an antibody is obtained which naturally lacks the light and heavy chain constant region 1 (CH 1), the variable region of the heavy chain of the antibody is cloned, and a single domain antibody (VHH) consisting of only one heavy chain variable region is constructed. =

4. As used herein, the term "epitope" refers to any antigenic determinant on an antigen to which the paratope of an antibody binds. An epitope typically comprises a chemically active surface group of a molecule, such as an amino acid or sugar side chain, and typically has specific three-dimensional structural features as well as specific charge features. For example, an epitope typically comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous or non-contiguous amino acids in a unique spatial conformation, which may be a "linear" epitope or a "conformational" epitope.

5. As used herein, the term "amino acid sequence" refers to the order in which amino acids are linked to each other to form a peptide chain (or polypeptide), and the amino acid sequence can only be read in one direction.

6. As used herein, the term "nucleic acid molecule" may be in the form of DNA or RNA. DNA forms include cDNA, genomic DNA, or synthetic DNA. The DNA may be single-stranded or double-stranded. The DNA may be a coding strand or a non-coding strand. The full-length sequence of the nucleotide molecule or a fragment thereof in the present invention can be generally obtained by a PCR amplification method or an artificial synthesis method.

7. As used herein, the term "nucleotide sequence" refers to the order of bases in DNA or RNA, i.e., A, T, G, C in DNA, or A, U, G, C in mRNA, including rRNA, tRNA, mRNA.

8. As used herein, the term "framework region" is a region of the framework, which varies widely about 110 amino acid sequences near the N-terminus of the H and L chains of an immunoglobulin, and the amino acid sequences of the other parts are relatively constant, whereby the light and heavy chains can be distinguished as variable (V) and constant (C) regions. The variable region comprises the hypervariable region HVR or complementarity determining region CDR and FR framework regions.

9. As used herein, the term "humanized" antibody refers to the antibody in which the variable region (VH or VHH) Fr region portion, the constant region portion (i.e., CH and CL regions) or all of the antibody is encoded by a human antibody gene. Humanized antibodies include chimeric antibodies, diabodies, and fully humanized antibodies.

10. As used herein, the term "Fc region" refers to the C-terminal region of an immunoglobulin, which is a functional building block consisting of only CH2 and CH3 in the heavy chain constant domain. Fc has no ability to bind antigen, however it has the property of having an extended half-life and has a constant amino acid sequence.

11. As used herein, the term "variable" means that certain portions of the variable regions in an antibody differ in sequence, which results in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the antibody variable region. It is concentrated in three segments of the light and heavy chain variable regions, known as complementarity determining regions or hypervariable regions. Herein, "variable region" is used interchangeably with "complementarity determining region".

12. As used herein, the term "expression vector" is a polynucleotide that is capable of being transcribed and translated into a polypeptide upon introduction into a suitable host cell.

13. The terms "hypervariable region," "complementarity determining region," "HVR," or "CDR," as used herein, refer to regions that are hypervariable in sequence and/or form structurally defined loops ("hypervariable loops") in an antibody variable domain region. Typically, a natural four-chain antibody comprises six HVRs or CDRs: three are present in VH (H1, H2, H3) and three are present in VL (L1, L2, L3). Based on the Chothia definition rules, exemplary CDRs (LCDR 1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR 3) are located at amino acid residues L26-L32 (L1), L50-L52 (L2), L91-L96 (L3), H26-H32 (H1), H52-H56 (H2), and H96-H101 (H3) (Chothia et al, J.mol.biol.196:901-917 (1987)). Based on the Kabat definition rules, exemplary CDRs (LCDR 1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR 3) are located at amino acid residues L24-L34 (L1), L50-L56 (L2), L89-L97 (L3), H31-H35 (H1), H50-H65 (H2), and H95-H102 (H3) (Kabat et al, sequences of Proteins ofImmunological Interest, the fifth edition, public Health Service, national Institutes of Health, bethesda, MD (1991)). Based on IMGT definition rules, exemplary CDRs (LCDR 1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR 3) are located at amino acid residues L27-L32 (L1), L50-L51 (L2), L89-L97 (L3), H26-H33 (H1), H51-H56 (H2), and H93-H102 (H3) (Honjo, T. And Alt, F.W. (1995) Immunoglobulin genes.academic Press pp.3-443). It is well known to those skilled in the art that the CDRs of an antibody can be defined in a variety of ways, such as Kabat definition rules based on sequence variability, chothia definition rules based on structural loop region positions, and reference tools for humanized design of antibodies based on CDR grafting (see J Mol biol.273:927-48, 1997). It will be appreciated by those skilled in the art that unless otherwise specified, the terms "CDR" and "complementarity determining region" of a given antibody or region thereof (e.g., variable region) are to be understood as encompassing complementarity determining regions defined in any of the above known schemes as described by the present invention. Although the scope of the present disclosure is based on the sequences shown by IMGT definition rules, amino acid sequences corresponding to other CDR definition rules shall also fall within the scope of the present invention.

14. The term "EC50" as used herein refers to the half maximal effect concentration (concentration for 50%of maximal effect), i.e. the concentration that causes 50% of the maximal effect (herein "ability to bind IL-17A").

15. The term "IC50" as used herein refers to a half inhibitory concentration (half maximal inhibitory concentration), i.e., a concentration that causes a 50% maximum inhibitory effect (herein, "ability to inhibit IL-17A and its receptor IL-17RA binding").

The technical scheme of the invention is as follows:

in a first aspect, the invention provides an antibody comprising:

(1) The amino acid sequence of the first single domain antibody comprises HCDR1 shown as SEQ ID NO. 1, HCDR2 shown as SEQ ID NO. 2 and HCDR3 shown as SEQ ID NO. 3; and/or; a sequence having at least 80% sequence identity to the amino acid sequence set forth in SEQ ID NO. 1-3;

(2) The amino acid sequence of the second single domain antibody comprises HCDR4 shown as SEQ ID NO. 4, HCDR5 shown as SEQ ID NO. 5 and HCDR6 shown as SEQ ID NO. 6; and/or; a sequence having at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO. 4-6.

Preferably, the amino acid sequence of the antibody comprises: an amino acid sequence obtained by at least one of modification, deletion, substitution and/or addition to the amino acid sequence shown in SEQ ID NO. 1-6.

Preferably, the amino acid sequence of the antibody comprises: amino acid sequences having a difference of 1, 2, 3, 4, 5, 6, 7 or 8 amino acids compared to the amino acid sequences shown in SEQ ID NO. 1-6.

SEQ ID NO. 1 is: ESLLRLYA.

SEQ ID NO. 2 is: HTTSDTT.

SEQ ID NO. 3 is: HVTSMRDSQNY.

SEQ ID NO. 4 is: GFSIHIYA.

SEQ ID NO. 5 is: ITRGGVT.

SEQ ID NO. 6 is: AGGTNGGY.

In some embodiments, the substitution of one or more amino acids may be conservative substitutions of one or more amino acids. Such conservative substitutions are preferably substitutions of one amino acid in the following groups (a) to (e) with another amino acid residue in the same group: (a) small aliphatic, non-polar or weakly polar residues: ala, ser, thr, pro and Gly; (b) Polar, negatively charged residues and (uncharged) amides: asp, asn, glu and Gln; (c) polar, positively charged residues: his, arg and Lys; (d) large aliphatic, nonpolar residues: met, leu, he, val and Cys; and (e) an aromatic residue: phe, tyr and Trp.

In some specific embodiments, conservative substitutions are as follows: ala to Gly or to Ser; arg to Lys; asn to Gln or to His; asp to Glu; cys to Ser; gln to Asn; glu to Asp; gly to Ala or to Pro; his to Asn or to Gln; lie to Leu or to Val; leu to Ile or to Val; lys to Arg, to gin, or to Glu; met to Leu, to Tyr or to Ile; phe to Met, to Leu, or to Tyr; ser to Thr; thr to Ser; trp to Tyr; tyr to Trp; and/or Phe to Val, to Ile or to Leu.

Preferably, the first or second single domain antibody further comprises at least 4 heavy chain framework regions for linking heavy chain variable regions.

Further, the heavy chain framework region comprises part or all of an antibody heavy chain framework region selected from human, murine, primate, or camelid sources or a variant thereof;

preferably, the antibody heavy chain framework regions or variants thereof comprise part or all of a source selected from camelids;

more preferably, the heavy chain framework regions of the antibodies or variants thereof are comprised in part or in whole selected from alpaca sources.

In a second aspect, the invention provides an antibody comprising a first single domain antibody and a second single domain antibody;

the structure of the first single domain antibody is FR1-HCDR1-FR2-HCDR2-FR3-HCDR3-FR4;

The structure of the second single domain antibody is FR5-HCDR4-FR6-HCDR5-FR7-HCDR6-FR8;

the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 are respectively shown as SEQ ID NO 1-3; or; amino acid sequences having a difference of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids compared to SEQ ID NO. 1-3;

the amino acid sequences of the HCDR4, the HCDR5 and the HCDR6 are respectively shown as SEQ ID NO. 4-6; or; amino acid sequence having a difference of 1, 2, 3, 4, 5, 6, 7 or 8 amino acids compared to SEQ ID NO. 4-6;

the amino acid sequences of the FR1, the FR2, the FR3 and the FR4 are respectively shown as SEQ ID NO 7-10; or an amino acid sequence having at least 80% sequence identity to SEQ ID NO. 7-10;

the amino acid sequences of the FR5, the FR6, the FR7 and the FR8 are respectively shown as SEQ ID NO. 11-14; or an amino acid sequence having at least 80% sequence identity to SEQ ID NO. 11-14;

the amino acid difference is realized by at least one mode of adding, deleting, modifying and/or substituting on the amino acid sequences shown in SEQ ID NO. 1-6.

SEQ ID NO. 7 is: DVQLVESGGGLVQPGGSLRLSCAAS.

SEQ ID NO. 8 is: MGWYRQLPGQEREWVAI.

SEQ ID NO. 9 is: NYRDSVKGRFTLSRDVATNTIYLQMTSLKPEDTAVYYC.

SEQ ID NO. 10 is: WGQGTQVTVSS.

SEQ ID NO. 11 is: EVQLVESGGGLVQPGGSLRLSCAAS.

SEQ ID NO. 12 is: MGWYRQAPGKQRELVAT.

SEQ ID NO. 13 is:

NNADSVKGRFTISRDNAKNTAYLQMNSLKPEDTAVYYCN。

SEQ ID NO. 14 is: WGQGTQVTVSS.

Preferably, the amino acid sequence of the HCDR1 is shown as SEQ ID NO. 1, the amino acid sequence of the HCDR2 is shown as SEQ ID NO. 2, the amino acid sequence of the HCDR3 is shown as SEQ ID NO. 3, the amino acid sequence of the HCDR4 is shown as SEQ ID NO. 4, the amino acid sequence of the HCDR5 is shown as SEQ ID NO. 5, and the amino acid sequence of the HCDR6 is shown as SEQ ID NO. 6.

Preferably, the amino acid sequence of FR1 is shown as SEQ ID NO. 7, the amino acid sequence of FR2 is shown as SEQ ID NO. 8, the amino acid sequence of FR3 is shown as SEQ ID NO. 9, the amino acid sequence of FR4 is shown as SEQ ID NO. 10, the amino acid sequence of FR5 is shown as SEQ ID NO. 11, the amino acid sequence of FR6 is shown as SEQ ID NO. 12, the amino acid sequence of FR7 is shown as SEQ ID NO. 13, and the amino acid sequence of FR8 is shown as SEQ ID NO. 14.

Preferably, the amino acid sequences of the first single domain antibody and the second single domain antibody are indirectly linked by a linker; or; and directly connected.

Further, the linker is (GGGGS) _n Wherein n is selected from 1, 2, 3, 4, 5 or 6;preferably, the linker is (GGGGS) ₃ 。

Preferably, the first single domain antibody and the second single domain antibody are linked in an optional order; or; the first single domain antibody and the second single domain antibody are connected in the order from the C end to the N end; or; the first single domain antibody and the second single domain antibody are linked in order from the N-terminus to the C-terminus.

Further preferably, the antibody is an anti-IL-17A antibody.

In a third aspect, the present invention provides a recombinant protein comprising an antibody according to any one of the first or second aspects above.

Preferably, the recombinant protein further comprises a biologically active protein or functional fragment thereof that aids in its expression and/or secretion, or extends its half-life in vivo.

Further preferably, the biologically active protein or functional fragment thereof is selected from at least one of His tag, GST tag, MBP tag, FLAG tag and SUMO tag, carboxy terminal peptide, serum albumin, prealbumin, immunoglobulin Fc domain, albumin binding polypeptide, elastin-like polypeptide.

Further preferably, the Fc domain is derived from a murine, camelid, human or primate antibody or a variant thereof;

Preferably, the immunoglobulin Fc domain is derived from a human IgG antibody, such as an IgG1 Fc, an IgG2 Fc, an IgG3 Fc or an IgG4 Fc, preferably an IgG1 Fc.

In some embodiments, one or more amino acid modifications may be introduced in the Fc region or Fc domain of an antibody provided herein, thereby producing an Fc region variant. An Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, igG2, igG3, or IgG4 Fc region) comprising amino acid modifications (e.g., substitutions, deletions, and insertions) at one or more amino acid positions.

In some embodiments, the recombinant protein may be a monomer, dimer, or multimer.

In a fourth aspect, the present invention provides a nucleic acid molecule encoding an antibody according to any one of the first or second aspects or a recombinant protein according to any one of the first or second aspects.

Specifically, the nucleic acid may be RNA, DNA or cDNA.

For some embodiments, the nucleic acids of the invention may also be in the form of a vector, may be present in and/or may be part of a vector, such as a plasmid, cosmid, or YAC. The vector may be an expression vector, which typically comprises at least one nucleic acid of the invention operably linked to one or more suitable expression control elements (e.g., promoters, enhancers, terminators, etc.).

In a fifth aspect, the invention provides an expression vector comprising the nucleic acid molecule.

Preferably, the expression vector is selected from the group consisting of DNA, RNA, viral vectors, plasmids, transposons, or combinations thereof.

In a sixth aspect, the present invention provides an antibody preparation comprising:

(1) The antibody of any one of the first or second aspects above or the recombinant protein; and

(2) A pharmaceutically acceptable carrier.

In particular, the pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration.

Further, the pharmaceutically acceptable carrier is selected from one or more of excipient, buffer, emulsifier, stabilizer, diluent, binder, preservative and lubricant.

In a seventh aspect, the present invention provides a kit comprising an antibody, recombinant protein or antibody preparation according to any one of the first or second aspects above;

Preferably, the kit further comprises a container for holding the antibody preparation.

In an eighth aspect, the present invention provides a drug conjugate comprising:

(1) The kit comprises the antibody or the recombinant protein according to any one of the first or second aspects; and;

(2) A coupling moiety coupled to (1).

In some embodiments, the coupling moiety comprises a detectable label, drug, toxin, cytokine, radionuclide, or enzyme.

In a ninth aspect, the present invention provides a pharmaceutical composition comprising an antibody, the recombinant protein, the nucleic acid molecule, the expression vector, the antibody preparation or the drug conjugate according to any one of the first or second aspects;

optionally, the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.

Specifically, the pharmaceutically acceptable auxiliary materials are selected from one or more of diluents, isotonic agents, buffering agents, emulsifying agents, thickening agents, sweeteners, disintegrating agents, preservatives, absorbents, dispersants, stabilizers, suspending agents, solvents, precipitation inhibitors, surfactants, glidants, binders, lubricants, hydration agents, emulsification accelerators, colorants, flavoring agents, ion exchangers, release agents, coating agents, flavoring agents or antioxidants.

In a tenth aspect, the invention provides the use of the antibody, the recombinant protein, the antibody preparation, the drug conjugate, the pharmaceutical composition of any one of the first or second aspects of the invention, wherein the use is at least one of the following:

(1) Preparing a detection reagent or a kit;

(2) Preparing a medicament for preventing and/or treating autoimmune diseases;

(3) Preparing medicine for preventing and/or treating cancer.

In particular, the method comprises the steps of, the autoimmune diseases include rheumatoid vasculitis, psoriasis, scleroderma, fibromyalgia, polymyalgia rheumatica, behcet's disease, macrovasculitis, addison's disease, rheumatoid arthritis, myasthenia gravis, kasmann's disease, idiopathic thrombocytopenic purpura, chronic atrophic gastritis, malignant rheumatoid arthritis, vasculitis, autoimmune hepatitis, alopecia areata, white spot disease, spondyloarthritis, lupus nephritis, bullous pemphigoid, pernicious anemia, psoriatic arthritis, idiopathic azoospermia, habitual abortion, focal scleroderma, idiopathic Addison's disease, inflammatory bowel disease, sarcoidosis, herpes gestational, polymyositis, barcedo's disease, adult Steve's disease, systemic lupus erythematosus, neuromyelitis, chronic lupus erythematosus, multiple sclerosis, systemic scleroderma progressive systemic sclerosis, dermatomyositis, autoimmune hemolytic anemia, periarteritis nodosa, aortic inflammatory syndrome, juvenile idiopathic arthritis, mixed connective tissue disease, sjogren's syndrome, allergic granulomatous vasculitis, allergic vasculitis, igG 4-related diseases, ANCA-related vasculitis, good-pasture syndrome, coban syndrome, linear IgA bullous dermatoses, slowly progressive type I diabetes, RS3PE syndrome, temporal arteritis, antiphospholipid antibody syndrome, eosinophilic fasciitis, green's barely syndrome, nonalcoholic steatohepatitis, primary biliary cirrhosis, acute glomerulonephritis, megaloblastic anemia, autoimmune neutropenia, hashimoto's disease, autoimmune adrenocortical insufficiency, primary hypothyroidism, primary hypothyroid disease, pemphigoid, acquired epidermolysis bullosa, vitiligo vulgaris, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, giant cell arteritis, amyotrophic lateral sclerosis, former disease, autoimmune optic neuropathy, celiac disease, ankylosing spondylitis, severe asthma, chronic urticaria transplantable immunity, familial mediterranean fever, eosinophilic chronic sinusitis, dilated cardiomyopathy, systemic mastocytosis or inclusion body myositis;

Further, the autoimmune disease is plaque psoriasis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or lupus nephritis.

In particular, the cancer includes oral cancer, respiratory cancer, eye cancer, skin cancer, head and neck cancer, laryngeal cancer, esophageal cancer, lymphoma, gastric cancer, bone cancer, digestive system cancer, liver cancer, lung cancer, kidney cancer, neuroblastoma, leukemia, glioblastoma, cholangiocarcinoma, bladder cancer, endometrial cancer, breast cancer, peritoneal cancer, cervical cancer, cholangiocarcinoma, choriocarcinoma, colorectal cancer, connective tissue cancer, melanoma, myeloma, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, basal cell carcinoma, rectal cancer, salivary gland carcinoma, sarcoma, squamous cell carcinoma, testicular cancer, thyroid cancer, uterine cancer, urinary system cancer, B-cell lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, hairy cell leukemia, or chronic myeloblastic leukemia.

In an eleventh aspect, the present invention provides a method for in vitro detection of IL-17A in a sample for non-diagnostic purposes, said method comprising the steps of:

(1) Contacting the antibody, the recombinant protein, the antibody preparation or the drug conjugate of any one of the first or second aspects with a sample to be tested;

(2) Detecting the antigen-antibody complex;

(3) And judging the result.

In a twelfth aspect, the present invention provides a method of preventing and/or treating an autoimmune disease, the method comprising:

administering to a subject in need thereof a therapeutically effective amount of an antibody, recombinant protein, antibody preparation or drug conjugate of any one of the above first or second aspects.

In a thirteenth aspect, the present invention provides a method of preventing and/or treating cancer, the method comprising:

The invention has the technical effects that:

(1) The tandem antibody 1-C11+1-F8 has good affinity, can be combined with target protein, and has obviously better combining ability than a positive antibody.

(2) The blocking effect is good, and the serial antibody 1-C11+1-F8 can block the Human IL-17A protein from activating 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc; the 1-C11+1-F8 blocking effect is significantly better than that of the positive control antibody.

(3) The stability is strong, the thermal denaturation Tm value and Tagg are higher, the Tm value of 1-C11+1-F8 is 62.98, and the Tagg value is 62.4, which is superior to positive antibody.

Drawings

FIG. 1 shows SDS-PAGE results of IL-17A recombinant proteins. Wherein M is a protein marker, lane 1 is a sample before IL-17A recombinant protein is refined, and lane 2 is a sample after IL-17A recombinant protein is refined.

FIG. 2 shows the results of alpaca stock flow assay.

FIG. 3 shows the results of the yeast monoclonal FACS assay.

FIG. 4 shows SDS-PAGE results of tandem single domain antibodies 1-C11+1-F8, wherein the left band is Marker and the right band is 1-C11+1-F8 in FIG. 4.

FIG. 5 shows the results of ELISA assays for tandem single domain antibody affinity.

FIG. 6 shows the results of ELISA assays for positive control antibody affinity.

FIG. 7 shows the detection of binding of IL-17A recombinant protein to reporter cell lines by FACS.

FIG. 8 shows the experimental results of IL-17A recombinant protein activation reporter cell lines.

FIG. 9 shows the results of an experiment for blocking IL-17A recombinant protein by the positive antibody Ixekizumab.

FIG. 10 shows the experimental results of blocking function detection of tandem single domain antibodies.

FIG. 11 shows the results of the test for blocking function of the positive control antibody.

FIG. 12 shows the results of thermostability assays for tandem single domain antibodies.

FIG. 13 shows the results of the thermal stability test of the positive control antibody.

Detailed Description

The present invention will be described in further detail with reference to the following examples, which are not intended to limit the present invention, but are merely illustrative of the present invention. The experimental methods used in the following examples are not specifically described, but the experimental methods in which specific conditions are not specified in the examples are generally carried out under conventional conditions, and the materials, reagents, etc. used in the following examples are commercially available unless otherwise specified.

The experimental reagent of the invention:

agar (Sigma, cat#a1296); peptone (Sigma, cat# 93926); yeast extract (OXOID, cat#: LP 0021); sodium chloride (Allatin, CAT#: C111533); potassium chloride (aladine, cat#: P112133); magnesium sulfate (national medicine, cat#: 10013018); magnesium chloride (national medicine, cat#: 10012818); glucose (Innovative, CAT#: GT 1991); sfiI (NEB, CAT#: R0123L); t4 DNAliase (TaKaRa, CAT#: 2011A); primeScript ^TM II 1st Strand cDNA Synthesis Kit (TaKaRa, CAT#: 6210B); nuHi power mix (new sea creature, cat#: NH 9303); 3M sodium acetate (pH 5.2-6) (Sigma, CAT#: 126-96-5); DNA fragment recovery kit (TakaRa, CAT#: 9761); glue recovery kit (Qiagen, CAT#: 28706); the Tiangen plasmid large drawing kit (Tiangen, CAT#: DP 117); HRP-Anti-M13 (iCarTab); PE-anti-Human IgG (eBioscience, cat#: 12-4998-82); PE-strepitavidin (bioleged, 405204); rabbit anti-Llama IgG (H+L) Secondary Antibody [ HRP ](Novus, cat#nbp1-75095); SS320 competence (iCarTab); pComF phage display vector (iCarTab); BL21 competence (Biomed, BC 201-02); NHS-biotin (APExBIO, CAT#: A8002); HRP-strepitavidin (Boster, CAT#: BA 1088); HRP-protein a (Boster, BA 1080);ProA Biosensors(Sartorius,CAT#:18-5010)；PBS(Gbico,CAT#14190-250)；DMEM(Gbico,CAT#41965-062)；RPMI1640(Gbico,CAT#61870044)；FBS(VivaCell,CAT#C04001-500)；Genomic DNA Purification Kit(Lifetech，CAT#K0512)；Mouse-IL-17A-His(ACRO，CT8-M5240)；Bright-Lite Luciferase Assay System(Vazyme,CAT#DD1204-01)；NHS-biotin(APExBIO,CAT#:A8002)。

experiment consumable:

50mL Falcon centrifuge tube (Corning, CAT # 352070); electric stun cup (Bio-Rad 0.2 cm); RNase free 1.5mL EP tube (QSP, CAT#: 509-GRD-Q); 200. Mu.L RNase free PCR tube (Axygen, PCR-02D-C); t125 shake flask (Corning, CAT# 431143); 15mL Falcon centrifuge tube (Corning, CAT # 430052); 6-well plate (Corning, cat#3516); 96-well plates (Corning, cat#3365); 96 Kong Heiban (F-BOTTOM (CHIMNEY WELL) BLACK).

Experimental facilities:

an electrotransport device (Eppendorf Multiporator); centrifuge (Thermo FRESCO-17); constant temperature incubator (Shanghai extract macro DNP-9052); constant temperature shake incubator (refined Qi CO-O6U); ultra clean bench (Sujing Antai SW-CJ-1 FD); PCR instrument (Applied Biosystems ABI 2720); biosafety cabinet (halr, HR40-IIA 2); a flow cytometer (Thermo Attune Nxt flow cytometer); thermo 3111CO ₂ An incubator; forteBio OCTET R2.

The primers used for screening and cloning VHH fragments and constructing nanobodies are designed by referring to the following documents:

Maass DR,Sepulveda J,Pernthaner A,Shoemaker CB.Alpaca(Lama pacos)as a convenient source of recombinant camelid heavy chain antibodies(VHHs).J Immunol Methods.2007；324(1-2):13-25。

Lin,J,Gu,Y,Xu,Y et al.Characterization and applications of nanobodies against Pseudomonas aeruginosa exotoxin a selected from single alpaca B cells.Biotechnol Biotechnol Equip 2020；34:1028-37。

Studies on design of singledomain antibodies by AlpacaVHH phage library and high throughput sequencing toconstruct Fab antibody purification system(http://hdl.handle.net/10232/00030916)。

EXAMPLE 1IL-17 nanobody screening method

1.1 preparation of IL-17A (Human) recombinant proteins (antigens)

Retrieving the sequence information (AA Gly 24-Ala155, shown as SEQ ID NO: 15) of Human IL-17A (Q16552-1) from a UniProt database, adding a 6 XHis tag at the C end, performing gene synthesis according to prokaryotic codon optimization, and subcloning into a pET28a vector; after verification of Sanger sequencing, plasmid extraction was performed.

Transforming the recombinant plasmid into BL21 competent, inducing overnight with 0.5mM IPTG, and collecting bacterial liquid for cleavage; the recombinant protein was purified using a nickel column.

SDS-PAGE detects the purity of the target protein, and the results show that the purity is >90% (FIG. 1).

SEQ ID NO:15:

MTPGKTSLVSLLLLLSLEAIVKAGITIPRNPGCPNSEDKNFPRTVMVNLNI HNRNTNTNPKRSSDYYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINAD GNVDYHMNSVPIQQEILVLRREPPHCPNSFRLEKILVSVGCTCVTPIVHHVA。

1.2 alpaca immunization

2 Alpaca (Alpaca) are immunized by the prepared recombinant antigen in a subcutaneous multipoint immunization mode, 6 times are immunized at intervals of 21 days, and after 10 days of last immunization, peripheral blood is collected and ELISA detection of immunization titer is carried out.

The immune titers of alpaca after 6 rounds of immunization all meet the requirements (see table 1).

TABLE 1 results of immunotiter assays

1.3 construction of antibody Yeast libraries

(1) PBMC isolation and VHH antibody fragment cloning:

collecting 100mL of peripheral blood anticoagulation sample, and separating PBMC cells by using lymphocyte separation liquid;

RNA extraction using PrimeScript ^TM II 1st Strand cDNA Synthesis Kit, performing reverse transcription to prepare cDNA;

the VHH fragment was PCR amplified.

(2) Construction of Single-Domain antibody Yeast display library

1.4 Yeast display library panning and screening:

using the prepared IL-17A antigen, incubation with streptavidin magnetic beads, adding yeast liquid to the antigen-bound magnetic beads, and spin incubation at 4 ℃ for 60 minutes for 2 rounds of magnetic sorting of the constructed yeast display library using streptavidin magnetic beads. After sorting, the saccharomycete liquid is coated on an SDCAA plate, monoclonal culture is selected, and flow analysis is carried out after 48h of induced expression. Incubation with Biotin-IL-17A-His for 1h, using PE strepitavidin for the secondary antibody, and flow detection after incubation was completed.

According to the flow detection result (figure 2), after the second magnetic separation, the yeast positive rate is 37.9%, positive clones are remarkably enriched, the separated products are directly coated on an SDCAA plate, and single clones are selected for flow detection.

1.5 FACS screening

After sorting, the saccharomycete liquid is coated on an SDCAA plate, monoclonal culture is selected, after induction expression is carried out for 48 hours, the monoclonal antibody is incubated with Biotin-antigen, and after incubation is completed, flow detection is carried out by using PE-strepitavidin for the secondary antibody.

The results are shown in FIG. 3, and IL17A target monoclonal and target binding conditions are detected by FACS; and comparing the amino acid sequences of the candidate single-domain antibodies obtained by sequencing, and selecting candidate antibodies with different CDR region amino acid sequences to construct eukaryotic expression vectors.

1.6 identification of antibody sequences

Enriching positive clones; and selecting the enriched single gram drop, performing Phage ELISA identification, and performing sequencing analysis on clones to obtain the nucleic acid and amino acid sequence information of the candidate single domain antibody. 20 monoclonals are randomly selected for sequencing analysis, the sequence difference is large, and the library diversity is good. The potential post-translational modification sites were analyzed by the In silico method against the amino acid sequence information of the CDR regions of the candidate single domain antibodies.

1.7 antibody expression purification

According to ELISA detection results of candidate antibodies, positive clones are selected, the obtained VHH antibody sequences are respectively subjected to gene synthesis, and subcloned into an expression vector pcDNA3.4-hIgG1-Fc in series with human IgG1 Fc. After the vector is verified by sequencing, the Qiagen plasmid megapump kit is used for preparing the endotoxin-removing plasmid for standby.

And taking out the LVTransm transfection reagent and the single-chain antibody expression vector from the refrigerator, thawing at room temperature, and blowing up and down by a pipetting gun to completely mix uniformly. The PBS buffer was removed and warmed to room temperature. Taking 2mL of PBS to one hole of a 6-hole plate, respectively adding 130 mug antibody expression vector, blowing up and down by a pipette, fully and uniformly mixing, adding 400 mug LVTransm, immediately blowing up and down by the pipette, uniformly mixing, and standing for 10 minutes at room temperature.

The DNA/LVTransm complex was added to 30mL of 293F cells, and the mixture was thoroughly mixed with gentle shaking. The cells were exposed to 5% CO at 37 ℃ ₂ After culturing for 6-8 hours at 130rpm in the incubator, 50mL of fresh 293 cell culture medium was added and the cells were returned to the incubator for continued culturing.

After 7 days of continuous culture, the culture supernatant was collected by centrifugation, filtered with a 0.45 μm filter membrane, and the filtrate was transferred to a sterile centrifuge tube and the antibody was purified using a Protein A column.

The procedure for purifying antibodies on Protein A column is as follows:

1) Samples containing the target antibodies were added to the EP tube and mixed by gently inverting the tube.

2) EP tubes were mixed at room temperature or incubated on a rotator, (1-4 hours or overnight) and 100mM PMSF was added to prevent protein degradation.

3) The magnetic beads were collected using a magnetic separation rack and the supernatant was discarded.

4) To the EP tube, 1mL of binding/washing buffer was added and thoroughly mixed, the beads were collected using a magnetic rack and the supernatant was discarded, and the washing step was repeated three times.

5) To the EP tube, 500. Mu.L of elution buffer was added, and resuspended rapidly with pipetting or vortexing, and then incubated at room temperature (about 25 ℃) for 5 minutes either in a tumble mixer or by manually gently tumbling the EP tube.

6) Magnetic beads were collected using a magnetic separation rack and the supernatant containing the eluted antibodies was transferred to a clean EP tube.

7) Steps 1) and 2) were repeated twice.

8) To each 500. Mu.l of eluate, 1/10 of a neutralization buffer was added to neutralize the pH in order to maintain the biological activity of the antibody and avoid inactivation of the antibody.

9) Binding/washing buffer: 1 XPBS, pH 7.0.

Elution buffer: (1) 0.1M glycine, pH 2-3 (2) 0.1M NaAc-HAc, pH 3.6.

Neutralization buffer: 1M Tris, pH 8.5.

Magnetic bead regeneration buffer: 0.1M NaOH.

Example 2 preparation of tandem Single Domain antibodies

2.1 screening of anti-IL-17A Single-Domain antibodies

The inventor finally obtains 14 anti-IL-17A single domain antibodies through screening of immune alpaca and yeast library. In the detection of the blocking activity of the antibody, the blocking effect of a part of single domain antibodies is weaker than that of a positive antibody Ixekizumab although the single domain antibodies can block the Human IL-17A protein from activating a downstream target protein. Thus, the inventors have tandem-enhanced blocking effects with two of the anti-IL-17A single domain antibodies. Two anti-IL-17A single domain antibodies were 1-C11 and 1-F8.

The amino acid sequence of the first single domain antibody 1-C11 is shown as SEQ ID NO. 16.

SEQ ID NO:16:

DVQLVESGGGLVQPGGSLRLSCAASESLLRLYAMGWYRQLPGQEREWV AIHTTSDTTNYRDSVKGRFTLSRDVATNTIYLQMTSLKPEDTAVYYCHVTSM RDSQNYWGQGTQVTVSS。

The nucleotide sequence of the coded single-domain antibody 1-C11 is shown as SEQ ID NO. 17.

SEQ ID NO:17：

GATGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGAAAGCCTCCTCAGGTTGTATGCCATGGGCTGGTACCGCCAACTTCCAGGGCAGGAGCGCGAGTGGGTCGCAATACACACTACTAGTGACACCACTAATTATAGAGACTCCGTGAAGGGCCGATTCACGCTCTCCAGAGACGTCGCCACGAACACGATTTATCTCCAAATGACCAGCCTCAAACCTGAAGACACGGCCGTCTATTATTGTCATGTTACTTCCATGAGAGATTCACAAAACTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCG。

The amino acid sequence of the second single domain antibody 1-F8 is shown as SEQ ID NO. 18.

SEQ ID NO:18:

EVQLVESGGGLVQPGGSLRLSCAASGFSIHIYAMGWYRQAPGKQRELVA TITRGGVTNNADSVKGRFTISRDNAKNTAYLQMNSLKPEDTAVYYCNAGGT NGGYWGQGTQVTVSS。

The nucleotide sequence of the coded single domain antibody 1-F8 is shown as SEQ ID NO. 19.

SEQ ID NO:19:

GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGCAGCCGGGGGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGATTTAGTATCCACATCTATGCCATGGGCTGGTACCGCCAGGCTCCAGGGAAGCAGCGCGAGCTGGTCGCAACTATTACTAGAGGTGGTGTAACAAATAATGCAGACTCCGTGAAGGGGCGATTCACCATCTCCAGAGACAACGCCAAGAACACGGCGTATCTGCAAATGAACAGCCTGAAACCTGAGGACACGGCCGTCTATTACTGTAATGCAGGTGGGACGAACGGGGGCTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCA。

2.2 preparation of tandem Single Domain antibody 1-C11+1-F8

Candidate antibody is prepared according to VHH- (GGGGS) ₃ The form of VHH-IgG 1Fc was constructed as a bivalent single domain antibody and purified using ProteinA magnetic beads, and the amino acid sequence of IgG1Fc was shown in SEQ ID NO. 20.

SEQ ID NO:20：

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK。

The nucleotide sequence of the coding SEQ ID NO. 20 is shown as SEQ ID NO. 21.

SEQ ID NO:21：

GACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCC CATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCACGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAAtaa。

The method comprises the following specific steps:

1) The two anti-IL-17A single domain antibody sequences are subjected to gene synthesis and subcloned into an expression vector pcDNA3.4-hIgG1-Fc in series with human IgG1 Fc. After the vector is verified to be correct by sequencing, preparing endotoxin-removing plasmids for later use by using a Qiagen plasmid large-pump kit;

2) And taking out the LVTransm transfection reagent and the single-chain antibody expression vector from the refrigerator, thawing at room temperature, and blowing up and down by a pipetting gun to completely mix uniformly. The PBS buffer was removed and warmed to room temperature. Taking 2mL of PBS to one hole of a 6-hole plate, respectively adding 130 mug antibody expression vector, blowing up and down by a pipette, fully and uniformly mixing, adding 400 mug LVTransm, immediately blowing up and down by the pipette, uniformly mixing, and standing for 10 minutes at room temperature.

3) The DNA/LVTransm complex was added to 30mL of 293F cells, and the mixture was thoroughly mixed with gentle shaking. The cells were exposed to 5% CO at 37 ℃ ₂ After culturing for 6-8 hours at 130rpm in the incubator, 50mL of fresh 293 cell culture medium was added and the cells were returned to the incubator for continued culturing.

4) After 7 days of continuous culture, the culture supernatant was collected by centrifugation, filtered with a 0.45 μm filter membrane, and the filtrate was transferred to a sterile centrifuge tube, and the antibody was purified using a Protein A column, to finally obtain the tandem single domain antibody 1-C11+1-F8.

SDS-PAGE results of the tandem single domain antibody 1-C11+1-F8 are shown in FIG. 4, and the results show that the molecular weight of the candidate antibody is in accordance with the expected molecular weight and the purity of the candidate antibody can be used for the next experiment.

Example 3 tandem single domain antibody affinity assay

1 preparation of positive control antibody Ixekizumab

Gene synthesis of Ixekizumab heavy chain and light chain variable region (the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO:22, the amino acid sequence of the light chain variable region is shown as SEQ ID NO: 23), subcloning the heavy chain variable region into pcDNA3.4-hIgG4 (the amino acid sequence of IgG4 is shown as SEQ ID NO: 24) vector, subcloning the light chain variable region into pcDNA3.4-hIgKc vector (the amino acid sequence of IgG KC is shown as SEQ ID NO: 25); after verification by Sanger sequencing, the plasmid megapump kit is used for preparing the endotoxin-removing plasmid for standby.

And taking out the LVTransm transfection reagent and the heavy chain and light chain expression vector from the refrigerator, thawing at room temperature, and blowing up and down by a pipetting gun to mix completely. The PBS buffer was removed and warmed to room temperature. Taking 2mL of PBS to one hole of a 6-hole plate, respectively adding 50 mug of heavy chain and light chain expression vectors, fully and uniformly mixing the heavy chain and the light chain expression vectors by up-and-down blowing of a pipette, adding 300 mug of LVTransm, immediately and uniformly mixing the LVTransm by up-and-down blowing of the pipette, and standing for 10 minutes at room temperature.

Adding the above DNA/LVTransm complex into 100mL of 293F cells, gently shaking, mixing, and placing the cells at 37deg.C and 5% CO ₂ Incubator, 130RPM continued to culture.

After continuous cultivation for 5-7 days, the culture supernatant was collected by centrifugation, filtered with a 0.45 μm filter membrane, and the filtrate was transferred to a sterile centrifuge tube and the antibody was purified using a Protein A column.

SDS-PAGE detects the purity of the target antibody protein, and the result shows that the protein purity is >95%.

SEQ ID NO:22:

QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEW MGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARY DYFTGTGVYWGQGTLVTVSS。

SEQ ID NO:23:

DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQL LIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQ GTKLEIK。

SEQ ID NO:24:

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK。

SEQ ID NO:25:

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC。

2ELISA detection of Human IL-17A recombinant protein and reference antibody binding Activity

(1) The IL-17A recombinant protein was diluted with sterile CBS to a final concentration of 2. Mu.g/mL. A new 96-well plate is taken, 100 mu L/well is added for coating overnight at 4 ℃;

(2) The antigen coating was removed and washed 3 times with PBST (0.5% tween);

(3) Blocking was performed at 37℃for 2 hours with the addition of 200. Mu.L/well of 3% MPBS;

(4) After removal of the blocking buffer, the well plate was washed 3 times with PBST;

(5) The positive control antibody Ixekizumab is diluted to 10 mug/ml by PBS, 7 points are diluted 5 times, 100 mug/well is added into an ELISA plate, and the incubation is carried out for 1 hour at room temperature, and the control well is PBS;

(6) Remove the liquid in the wells and wash 3 times with PBST;

(7) Secondary anti-HRP-protein a (Boster, BA 1080) 1 was added: 10000 diluted, adding into the ELISA plate according to 100 mu L/hole, and incubating for 1 hour at room temperature;

(8) After removing the liquid from the wells, the well plate was washed 3 times with PBST;

(9) Adding 100 mu L/hole TMB color development liquid;

(10) Incubating for 15 minutes at room temperature in a dark place;

(11) Add 50. Mu.L/Kong Zhongzhi solution (2M HCL);

(12) OD450 values within wells were read using a microplate reader. As shown in Table 2, the positive antibodies bind well to IL-17A antigen protein and can be used for immunization.

Table 2 detection of binding Activity of human IL17A to Positive antibodies

3ELISA detection of tandem Single Domain antibody affinity

Coating the purified single domain antibody with 2 mug/mL of a 96-well ELISA plate, adding Biotin-IL-17A-His, diluting 7 points with a 5-fold gradient at an initial concentration of 10 mug/mL, and performing ELISA detection by using HRP-strepitavdin. The results showed that the EC50 of 1-C11+1-F8 was 2.233 (FIG. 5), well below 10.06 of the positive control antibody (FIG. 6). Therefore, the tandem single domain antibody can bind to the target protein with higher binding capacity than the positive antibody.

Example 4 tandem single domain antibody blocking function detection

Construction of 1IL-17A reporter cell line

Based on the amino acid sequence information of IL-17RA (UniProtKB: Q96F46, SEQ ID NO: 26) and IL-17RC (UniProtKB: Q8NAC3, SEQ ID NO: 27), a lentiviral expression vector is constructed and lentivirus is packaged, 293 cells are co-infected, recombinant 293 cells which simultaneously overexpress the two receptors are screened, NFKB-Luciferase (the amino acid sequence of which is shown as SEQ ID NO:28, the nucleotide sequence of which is shown as SEQ ID NO: 29) and ACT1 gene (the nucleotide sequence of which is shown as SEQ ID NO: 30) are further stably transformed, and an IL-17A reporter cell strain 293F-IL-17 RA-17 Rc-ACT 1-NFkB-Luc is constructed.

SEQ ID NO:26:

MGAARSPPSAVPGPLLGLLLLLLGVLAPGGASLRLLDHRALVCSQPGLNCTVKNSTCLDDSWIHPRNLTPSSPKDLQIQLHFAHTQQGDLFPVAHIEWTLQTDASILYLEGAELSVLQLNTNERLCVRFEFLSKLRHHHRRWRFTFSHFVVDPDQEYEVTVHHLPKPIPDGDPNHQSKNFLVPDCEHARMKVTTPCMSSGSLWDPNITVETLEAHQLRVSFTLWNESTHYQILLTSFPHMENHSCFEHMHHIPAPRPEEFHQRSNVTLTLRNLKGCCRHQVQIQPFFSSCLNDCLRHSATVSCPEMPDTPEPIPDYMPLWVYWFITGISILLVGSVILLIVCMTWRLAGPGSEKYSDDTKYTDGLPAADLIPPPLKPRKVWIIYSADHPLYVDVVLKFAQFLLTACGTEVALDLLEEQAISEAGVMTWVGRQKQEMVESNSKIIVLCSRGTRAKWQALLGRGAPVRLRCDHGKPVGDLFTAAMNMILPDFKRPACFGTYVVCYFSEVSCDGDVPDLFGAAPRYPLMDRFEEVYFRIQDLEMFQPGRMHRVGELSGDNYLRSPGGRQLRAALDRFRDWQVRCPDWFECENLYSADDQDAPSLDEEVFEEPLLPPGTGIVKRAPLVREPGSQACLAIDPLVGEEGGAAVAKLEPHLQPRGQPAPQPLHTLVLAAEEGALVAAVEPGPLADGAAVRLALAGEGEACPLLGSPGAGRNSVLFLPVDPEDSPLGSSTPMASPDLLPEDVREHLEGLMLSLFEQSLSCQAQGGCSRPAMVLTDPHTPYEEEQRQSVQSDQGYISRSSPQPPEGLTEMEEEEEEEQDPGKPALPLSPEDLESLRSLQRQLLFRQLQKNSGWDTMGSESEGPSA。

SEQ ID NO:27:

MPVPWFLLSLALGRSPVVLSLERLVGPQDATHCSPVSLEPWGDEERLRVQFLAQQSLSLAPVTAATARTALSGLSGADGRREERGRGKSWVCLSLGGSGNTEPQKKGLSCRLWDSDILCLPGDIVPAPGPVLAPTHLQTELVLRCQKETDCDLC LRVAVHLAVHGHWEEPEDEEKFGGAADSGVEEPRNASLQAQVVLSFQAYPTARCVLLEVQVPAALVQFGQSVGSVVYDCFEAALGSEVRIWSYTQPRYEKELNHTQQLPDCRGLEVWNSIPSCWALPWLNVSADGDNVHLVLNVSEEQHFGLSLYWNQVQGPPKPRWHKNLTGPQIITLNHTDLVPCLCIQVWPLEPDSVRTNICPFREDPRAHQNLWQAARLQLLTLQSWLLDAPCSLPAEAALCWRAPGGDPCQPLVPPLSWENVTVDKVLEFPLLKGHPNLCVQVNSSEKLQLQECLWADSLGPLKDDVLLLETRGPQDNRSLCALEPSGCTSLPSKASTRAARLGEYLLQDLQSGQCLQLWDDDLGALWACPMDKYIHKRWALVWLACLLFAAALSLILLLKKDHAKGWLRLLKQDVRSGAAARGRAALLLYSADDSGFERLVGALASALCQLPLRVAVDLWSRRELSAQGPVAWFHAQRRQTLQEGGVVVLLFSPGAVALCSEWLQDGVSGPGAHGPHDAFRASLSCVLPDFLQGRAPGSYVGACFDRLLHPDAVPALFRTVPVFTLPSQLPDFLGALQQPRAPRSGRLQERAEQVSRALQPALDSYFHPPGTPAPGRGVGPGAGPGAGDGT。

SEQ ID NO:28:

MEDAKNIKKGPAPFYPLEDGTAGEQLHKAMKRYALVPGTIAFTDAHIEVDITYAEYFEMSVRLAEAMKRYGLNTNHRIVVCSENSLQFFMPVLGALFIGVAVAPANDIYNERELLNSMGISQPTVVFVSKKGLQKILNVQKKLPIIQKIIIMDSKTDYQGFQSMYTFVTSHLPPGFNEYDFVPESFDRDKTIALIMNSSGSTGLPKGVALPHRTACVRFSHARDPIFGNQIIPDTAILSVVPFHHGFGMFTTLGYLICGFRVVLMYRFEEELFLRSLQDYKIQSALLVPTLFSFFAKSTLIDKYDLSNLHEIASGGAPLSKEVGEAVAKRFHLPGIRQGYGLTETTSAILITPEGDDKPGAVGKVVPFFEAKVVDLDTGKTLGVNQRGELCVRGPMIMSGYVNNPEATNALIDKDGWLHSGDIAYWDEDEHFFIVDRLKSLIKYKGYQVAPAELESILLQHPNIFDAGVAGLPDDDAGELPAAVVVLEHGKTMTEKEIVDYVASQVTTAKKLRGGVVFVDEVPKGLTGKLDARKIREILIKAKKGGKIAV。

SEQ ID NO:29:

atggaagatgccaaaaacattaagaagggcccagcgccattctacccactcgaagacgggaccgccggcgagcagctgcacaaagccatgaagcgctacgccctggtgcccggcaccatcgcctttaccgacgcacatatcgaggtggacattacctacgccgagtacttcgagatgagcgttcggctggcagaagctatgaagcgctatgggctgaatacaaaccatcggatcgtggtgtgcagcgagaatagcttgcagttcttcatgcccgtgttgggtgccctgttcatcggtgtggctgtggccccagctaacgacatctacaacgagcgcgagctgctgaacagcatgggcatcagccagcccaccgtcgtattcgtgagcaagaaagggctgcaaaagatcctcaacgtgcaaaagaagctaccgatcatacaaaagatcatcatcatggatagcaagaccgactaccagggcttccaaagcatgtacaccttcgtgacttcccatttgccacccggcttcaacgagtacgacttcgtgcccgagagcttcga ccgggacaaaaccatcgccctgatcatgaacagtagtggcagtaccggattgcccaagggcgtagccctaccgcaccgcaccgcttgtgtccgattcagtcatgcccgcgaccccatcttcggcaaccagatcatccccgacaccgctatcctcagcgtggtgccatttcaccacggcttcggcatgttcaccacgctgggctacttgatctgcggctttcgggtcgtgctcatgtaccgcttcgaggaggagctattcttgcgcagcttgcaagactataagattcaatctgccctgctggtgcccacactatttagcttcttcgctaagagcactctcatcgacaagtacgacctaagcaacttgcacgagatcgccagcggcggggcgccgctcagcaaggaggtaggtgaggccgtggccaaacgcttccacctaccaggcatccgccagggctacggcctgacagaaacaaccagcgccattctgatcacccccgaaggggacgacaagcctggcgcagtaggcaaggtggtgcccttcttcgaggctaaggtggtggacttggacaccggtaagacactgggtgtgaaccagcgcggcgagctgtgcgtccgtggccccatgatcatgagcggctacgttaacaaccccgaggctacaaacgctctcatcgacaaggacggctggctgcacagcggcgacatcgcctactgggacgaggacgagcacttcttcatcgtggaccggctgaagagcctgatcaaatacaagggctaccaggtagccccagccgaactggagagcatcctgctgcaacaccccaacatcttcgacgccggggtcgccggcctgcccgacgacgatgccggcgagctgcccgccgcagtcgtcgtgctggaacacggtaaaaccatgaccgagaaggagatcgtggactatgtggccagccaggttacaaccgccaagaagctgcgcggtggtgttgtgttcgtggacgaggtgcctaaaggactgaccggcaagttggacgcccgcaagatccgcgagattctcattaaggccaagaagggcggcaagatcgccgtg。

SEQ ID NO:30:

ATGCCACCTCAGTTGCAGGAAACTCGGATGAATAGAAGCATCCCCGTGGAAGTGGACGAGAGCGAGCCGTACCCTAGTCAGCTGCTGAAGCCGATCCCTGAGTACTCCCCGGAAGAGGAATCCGAACCACCAGCCCCCAACATTCGCAATATGGCCCCCAATAGCTTGTCCGCACCAACAATGCTGCACAACTCTTCTGGCGACTTCTCTCAGGCCCACTCCACCCTGAAACTGGCGAATCACCAGCGGCCTGTATCCCGGCAGGTGACCTGTCTGAGAACTCAGGTGCTTGAAGACTCCGAGGACTCTTTCTGTAGGCGGCATCCAGGTTTGGGCAAGGCGTTTCCGTCCGGCTGTTCCGCGGTTTCAGAGCCCGCTTCCGAAAGTGTCGTGGGCGCCCTGCCAGCCGAGCACCAGTTCTCCTTCATGGAAAAGCGGAACCAGTGGCTGGTCAGTCAGCTGAGCGCCGCGTCACCTGATACAGGTCACGATTCCGACAAGTCTGACCAGTCTCTGCCCAATGCGTCAGCCGATAGTCTCGGGGGCTCCCAGGAGATGGTGCAGAGACCACAGCCGCACAGAAACCGGGCCGGGCTTGATCTGCCCACCATTGATACAGGCTACGATTCCCAGCCCCAGGACGTCCTTGGCATTCGCCAGCTGGAAAGGCCTCTGCCCTTGACCTCCGTGTGTTACCCCCAGGACCTGCCCCGCCCTTTGAGAAGCCGGGAGTTTCCCCAGTTTGAGCCCCAACGATACCCTGCCTGTGCTCAGATGCTGCCTCCGAACCTGAGCCCACACGCTCCCTGGAACTACCACTATCACTGTCCCGGCAGCCCCGATCACCAGGTGCCTTATGGACACGACTACCCGCGGGCTGCATACCAGCAGGTCATACAGCCTGCCTTG CCGGGTCAGCCGCTGCCCGGAGCTTCTGTGCGCGGCCTGCACCCCGTTCAGAAAGTGATCCTGAACTATCCAAGCCCATGGGACCATGAAGAGAGACCAGCCCAAAGAGATTGCTCTTTTCCTGGGTTGCCTAGACACCAAGACCAGCCTCACCACCAGCCTCCCAATCGGGCAGGCGCCCCAGGCGAAAGTCTCGAGTGCCCCGCCGAACTCAGACCACAGGTCCCTCAGCCCCCTTCCCCCGCGGCAGTACCCAGACCCCCCTCTAACCCACCCGCCCGGGGAACGCTCAAGACTTCAAATCTCCCAGAAGAGCTGCGCAAAGTGTTCATAACCTACAGCATGGACACCGCTATGGAGGTGGTTAAGTTCGTCAACTTCCTGCTGGTCAATGGGTTCCAGACTGCAATCGACATTTTTGAGGATAGAATTCGGGGAATCGACATCATCAAGTGGATGGAGAGATACCTGCGGGATAAGACAGTGATGATTATCGTGGCCATTAGTCCCAAGTACAAGCAAGATGTGGAGGGCGCAGAATCACAGTTGGACGAAGACGAGCACGGACTCCATACAAAATATATCCACAGGATGATGCAGATCGAGTTCATTAAACAAGGCTCCATGAATTTCCGCTTCATACCGGTCCTGTTTCCAAACGCAAAAAAAGAGCATGTACCCACTTGGCTCCAGAATACCCATGTCTACTCCTGGCCCAAGAACAAGAAGAATATCCTGCTGCGCTTGCTCAGAGAAGAAGAGTATGTCGCCCCTCCAAGGGGGCCCCTCCCCACACTCCAAGTAGTGCCACTT。

Binding of 2IL-17A recombinant proteins to reporter cell lines

Resuscitating 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc cell lines from liquid nitrogen, and adjusting the cell state to the logarithmic growth phase;

dividing the cells into several parts, each cell number being 2×10 ⁵ A cell;

incubating IL-17A-His protein and target cells, and incubating for 1 hour at room temperature after fully mixing;

centrifugation at 800 Xg for 3 min at room temperature, removal of antibody-containing supernatant, washing of cells 3 times with PBS;

adding secondary antibody APC-His (1:500 dilution), fully mixing, and incubating for 30 minutes at room temperature in a dark place;

Centrifugation at 800 Xg for 3 min at room temperature, removal of the secondary antibody containing supernatant, washing the cells 3 times with PBS;

flow assays were performed using 500 μl PBS to resuspend cells.

FACS results show: the constructed IL-17A receptor over-expression cell strain can be combined with IL-17A, and the positive rate is more than 90 percent (figure 7).

The IL-17A recombinant protein is adopted to activate 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc. The results showed that the IL17A recombinant protein was effective in activating luciferase expression in 293F-IL17Ra/IL17 Rc-NFkB-Luc reporter cell lines (FIG. 8).

Functional experiments of 3Ixekizumab blocking IL-17A recombinant protein

The present example uses the positive antibody Ixekizumab to detect the validity of the fluorescence reporting system. The positive control antibody Ixekizumab was added to 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc cells together with the IL-17A recombinant protein, as shown in the results: the positive control antibody Ixekizumab inhibited IL17A protein binding to its membrane receptor and inhibited intracellular nfkb signaling, exhibiting a dose effect (fig. 9).

Blocking function of 4 tandem single domain antibody

Tandem single domain antibody blocking Activity assays were performed using the 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc reporter cell line. The results showed that IC50 of 1-C11+1-F8 was 0.7816. Mu.g/mL and that of the positive control antibody was 1.356. Mu.g/mL (FIGS. 10 and 11). Therefore, both the 1-C11+1-F8 and the positive control antibody can block the Human IL-17A protein from activating 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc, and the blocking effect of the tandem antibody 1-C11+1-F8 is better than that of the positive antibody.

Example 5 tandem Single Domain antibody stability detection

By detecting fluorescence change by differential scanning fluorescence (nanoDSF) technique, thermal denaturation and chemical denaturation of proteins can be detected under natural conditions, and the temperature (T) at which 50% of proteins are in an unfolded state can be precisely determined _m ) The temperature at which aggregation starts to occur (T _agg ) The method comprises the steps of carrying out a first treatment on the surface of the Thermal denaturation T _m Value sum T _agg Higher indicates that the antibody protein is more stable.

Taking 100 mu L of candidate antibody prepared in the earlier stage and Ixekizumab (the concentration of a sample is greater than 200 mu g/mL), centrifuging at 4 ℃ and 12000 Xg for 10min, sucking the sample by using a capillary tube, preparing two capillaries for each sample, taking the capillaries as parallel control, putting the capillaries into corresponding clamping grooves in sequence, ensuring that the capillaries are full of the sample, and carrying out detection analysis.

Experimental results:

as shown in fig. 12-13, the stability of the tandem antibody 1-c11+1-F8 was strong, tm=62.98, tagg=62.4, tm=56.1, tagg=61.86 for the positive control. The stability of the tandem antibody 1-C11+1-F8 is better than that of the positive antibody.

Application example 1 an antibody preparation

The antibody preparation comprises: tandem single domain antibody 1-C11+1-F8, buffer, surfactant, amino acid, tonicity agent, and the like.

In one embodiment of the invention, the preparation of the antibody preparation comprises: weighing all the materials, adding water for dissolving and uniformly mixing, and regulating the concentrations of all the components to obtain the composition: (100-200) mg/ml of tandem single domain antibody 1-C11+1-F8, (1-10) mM citrate buffer, (0.1-1% w/v) Tween 80, (100-200) mM arginine and (1-10)% sucrose, the pH of the formulation being 5.0-8.0.

Application example 2A kit

The kit comprises: tandem single domain antibody 1-C11+1-F8, recombinant proteins, antibody preparations and/or polyclonal antibodies, containers for loading antibody preparations, buffers, and the like.

In one embodiment of the invention, the kit comprises: (100-200) mg/ml of a buffer solution of serial single domain antibody 1-C11+1-F8 with pH of 5.0-8.0.

Application example 3 antibody drug conjugate

The antibody drug conjugate comprises: the tandem single domain antibody 1-C11+1-F8, recombinant protein, antibody preparation and/or polyclonal antibody, the medicine is physiologically active substance (such as nucleic acid, etc.) and the linker for connecting the antibody and the medicine (the linker comprises maleimide linker, val-Cit linker, SS linker and DMSS linker).

In one embodiment of the invention, the serial single domain antibody 1-C11+1-F8 is connected with the drug through an SS joint, and (100-200) mM aqueous solution is added and mixed uniformly at room temperature, and the joint reaction is terminated, thus obtaining the antibody drug conjugate.

Application example 4 pharmaceutical composition

The pharmaceutical composition comprises serial single domain antibodies 1-C11+1-F8, recombinant proteins, antibody preparations, polyclonal antibodies, nucleic acid molecules, biological expression vectors and/or host cells, and pharmaceutically acceptable auxiliary materials.

In one embodiment of the present invention, the preparation of the pharmaceutical composition comprises: preparing serial single domain antibody 1-C11+1-F8 with concentration of (100-200) mg/ml, adding sucrose (1-20 w/v), histidine (10-300) mM and Tween 80 (0.1-10)% to obtain the pharmaceutical composition.

Claims

1. An antibody, characterized in that: the antibody comprises:

2. The antibody of claim 1, wherein: the amino acid sequence of the antibody comprises: an amino acid sequence obtained by at least one of modification, deletion, substitution and/or addition to the amino acid sequence shown in SEQ ID NO. 1-6.

3. The antibody of claim 2, wherein: the amino acid sequence of the antibody comprises: amino acid sequences having a difference of 1, 2, 3, 4, 5, 6, 7 or 8 amino acids compared to the amino acid sequences shown in SEQ ID NO. 1-6.

4. An antibody according to any one of claims 1-3, characterized in that: the first or second single domain antibody further comprises at least 4 heavy chain framework regions for linking the heavy chain variable regions.

5. The antibody of claim 4, wherein: the heavy chain framework region comprises part or all of an antibody heavy chain framework region selected from human, murine, primate, or camelid sources or a variant thereof;

6. An antibody, characterized in that: the antibody comprises a first single domain antibody and a second single domain antibody;

7. The antibody of claim 6, wherein: the amino acid sequence of the HCDR1 is shown as SEQ ID NO. 1, the amino acid sequence of the HCDR2 is shown as SEQ ID NO. 2, the amino acid sequence of the HCDR3 is shown as SEQ ID NO. 3, the amino acid sequence of the HCDR4 is shown as SEQ ID NO. 4, the amino acid sequence of the HCDR5 is shown as SEQ ID NO. 5, and the amino acid sequence of the HCDR6 is shown as SEQ ID NO. 6.

8. An antibody according to any one of claims 1-7, wherein: the amino acid sequences of the first single-domain antibody and the second single-domain antibody are indirectly connected through a linker; or; and directly connected.

9. The antibody of claim 8, wherein: the linker is (GGGGS) _n Wherein n is selected from 1, 2, 3, 4, 5 or 6; preferably, the linker is (GGGGS) ₃ 。

10. An antibody according to any one of claims 1-9, characterized in that: the first single domain antibody and the second single domain antibody are connected in an optional sequence; or; the first single domain antibody and the second single domain antibody are connected in the order from the C end to the N end; or; the first single domain antibody and the second single domain antibody are linked in order from the N-terminus to the C-terminus.

11. An antibody according to any one of claims 1-10, characterized in that: the antibody is an anti-IL-17A antibody.

12. A recombinant protein, characterized in that: the recombinant protein comprising the antibody of any one of claims 1-11.

13. The recombinant protein according to claim 12, wherein: the recombinant protein also comprises a biologically active protein or functional fragment thereof that aids in its expression and/or secretion, or that extends its half-life in vivo.

14. The recombinant protein according to claim 13, wherein: the bioactive protein or functional fragment thereof is selected from at least one of His tag, GST tag, MBP tag, FLAG tag and SUMO tag, carboxyl terminal peptide, serum albumin, prealbumin, immunoglobulin Fc domain, albumin binding polypeptide and elastin-like polypeptide.

15. The recombinant protein according to claim 14, wherein: the immunoglobulin Fc domain is derived from a murine, camelid, human or primate antibody or a variant thereof;

16. A nucleic acid molecule characterized in that: the nucleic acid molecule encodes the antibody of any one of claims 1-11 or the recombinant protein of any one of claims 12-15.

17. An expression vector, characterized in that: the expression vector comprises the nucleic acid molecule of claim 16.

18. An antibody preparation, characterized in that: the antibody preparation comprises:

(1) The antibody of any one of claims 1-11 or the recombinant protein of any one of claims 12-15; and

(2) A pharmaceutically acceptable carrier.

19. A kit, characterized in that: the kit comprises the antibody of any one of claims 1-11, the recombinant protein of any one of claims 12-15, or the antibody preparation of claim 18;

20. A drug conjugate, characterized in that: the drug conjugate comprises:

(1) The antibody of any one of claims 1-11 or the recombinant protein of any one of claims 12-15; and;

(2) A coupling moiety coupled to (1).

21. A pharmaceutical composition characterized by: the pharmaceutical composition comprises the antibody of any one of claims 1-11, the recombinant protein of any one of claims 12-15, the nucleic acid molecule of claim 16, the expression vector of claim 17, the antibody preparation of claim 18, or the drug conjugate of claim 20;

22. Use of the antibody of any one of claims 1-11, the recombinant protein of any one of claims 12-15, the antibody preparation of claim 18, the drug conjugate of claim 20, the pharmaceutical composition of claim 21, characterized in that: the use is at least one of the following uses:

(1) Preparing a detection reagent or a kit;

(2) Preparing a medicament for preventing and/or treating autoimmune diseases;

(3) Preparing medicine for preventing and/or treating cancer.

23. Use according to claim 22, characterized in that: the autoimmune diseases include rheumatoid vasculitis, psoriasis, scleroderma, fibromyalgia, polymyalgia rheumatica, behcet's disease, macrovasculitis, addison's disease, rheumatoid arthritis, myasthenia gravis, kasmann's disease, idiopathic thrombocytopenic purpura, chronic atrophic gastritis, malignant rheumatoid arthritis, vasculitis, autoimmune hepatitis, alopecia areata, white spot disease, spondyloarthritis, lupus nephritis, bullous pemphigoid, pernicious anemia, psoriatic arthritis, idiopathic azoospermia, habitual abortion, focal scleroderma, idiopathic Addison's disease, inflammatory bowel disease, sarcoidosis, herpes gestational, polymyositis, barcedo's disease, adult Steve's disease, systemic lupus erythematosus, neuromyelitis, chronic lupus erythematosus, multiple sclerosis, systemic scleroderma progressive systemic sclerosis, dermatomyositis, autoimmune hemolytic anemia, periarteritis nodosa, aortic inflammatory syndrome, juvenile idiopathic arthritis, mixed connective tissue disease, sjogren's syndrome, allergic granulomatous vasculitis, allergic vasculitis, igG 4-related diseases, ANCA-related vasculitis, good-pasture syndrome, coban syndrome, linear IgA bullous dermatoses, slowly progressive type I diabetes, RS3PE syndrome, temporal arteritis, antiphospholipid antibody syndrome, eosinophilic fasciitis, green's barely syndrome, nonalcoholic steatohepatitis, primary biliary cirrhosis, acute glomerulonephritis, megaloblastic anemia, autoimmune neutropenia, hashimoto's disease, autoimmune adrenocortical insufficiency, primary hypothyroidism, primary hypothyroid disease, pemphigoid, acquired epidermolysis bullosa, vitiligo vulgaris, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, giant cell arteritis, amyotrophic lateral sclerosis, former disease, autoimmune optic neuropathy, celiac disease, ankylosing spondylitis, severe asthma, chronic urticaria transplantable immunity, familial mediterranean fever, eosinophilic chronic sinusitis, dilated cardiomyopathy, systemic mastocytosis or inclusion body myositis;

24. The use according to claim 22 or 23, wherein the cancer comprises oral cancer, respiratory cancer, eye cancer, skin cancer, head and neck cancer, laryngeal cancer, esophageal cancer, lymphoma, gastric cancer, bone cancer, digestive system cancer, liver cancer, lung cancer, kidney cancer, neuroblastoma, leukemia, glioblastoma, cholangiocarcinoma, bladder cancer, endometrial cancer, breast cancer, peritoneal cancer, cervical cancer, cholangiocarcinoma, choriocarcinoma, colorectal cancer, connective tissue cancer, melanoma, myeloma, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, basal cell carcinoma, rectal cancer, salivary gland cancer, sarcoma, squamous cell carcinoma, testicular cancer, thyroid cancer, uterine cancer, urinary system cancer, B-cell lymphoma, chronic lymphoblastic leukemia, acute lymphoblastic leukemia, hairy cell leukemia or chronic myeloblastic leukemia.

25. A method for in vitro detection of IL-17A in a sample for non-diagnostic purposes, characterized in that: the method comprises the following steps:

(1) Contacting the antibody of any one of claims 1-11, the recombinant protein of any one of claims 12-15, the antibody preparation of claim 18, or the drug conjugate of claim 20 with a sample to be tested;

(2) Detecting the antigen-antibody complex;

(3) And judging the result.

26. A method for preventing and/or treating autoimmune diseases, characterized in that: the method comprises the following steps:

administering to a subject in need thereof a therapeutically effective amount of the antibody of any one of claims 1-11, the recombinant protein of any one of claims 12-15, the antibody preparation of claim 18, or the drug conjugate of claim 20.

27. A method for preventing and/or treating cancer, characterized by: the method comprises the following steps: